Suchergebnisse - "Carlo-Stella, Carmelo"

PubPharm (9)

1

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma : long-term efficacy and safety from the phase II LOTIS-2 study

enthalten in: Haematologica | 2024

von Caimi, P. | Ai, W. | Alderuccio, J. | +13

2

In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine

enthalten in: EJHaem | 2024

von Caimi, P. | Hamadani, M. | Carlo-Stella, C. | +10

3

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

enthalten in: Blood advances | 2024

von Hamadani, M. | Spira, A. | Zhou, X. | +16

4

Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2022

von Hamadani, M. | Chen, L. | Song, Y. | +4

5

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma : a subgroup analysis from the LOTIS-2 study

enthalten in: Blood advances | 2022

von Alderuccio, J. | Ai, W. | Radford, J. | +14

6

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

enthalten in: Blood | 2022

von Calabretta, E. | Hamadani, M. | Zinzani, P. | +2

7

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2) : a multicentre, open-label, single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Caimi, P. | Ai, W. | Alderuccio, J. | +15

CommentIn: Lancet Oncol. 2021 Jun;22(6):741-742. - PMID 33989556

8

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

enthalten in: Blood | 2021

von Hamadani, M. | Radford, J. | Carlo-Stella, C. | +14

CommentIn: Blood. 2021 May 13;137(19):2568-2570. - PMID 33983420

9

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Kahl, B. | Hamadani, M. | Radford, J. | +12

1
[1]